APcK110 [1001083-74-4]

TargetMol Chemicals

APcK110 [1001083-74-4]

72

1001083-74-4

Research Use Only

APcK110

C20H16FN3O2

349.36

APcK110 is a novel Kit inhibitor . APcK110 inhibits proliferation of the mastocytosis cell line HMC1.2 and the SCF-responsive cell line OCI/AML3 in a dose-dependent manner . APcK110 is a more potent inhibitor of OCI/AML3 proliferation than the clinically used Kit inhibitors imatinib and dasatinib and at least as potent as cytarabine. APcK110 inhibits the phosphorylation of Kit, Stat3, Stat5, and Akt in a dose-dependent fashion, showing activity of APcK110 on Kit and its downstream signaling pathways . APcK110 may have potent application in AML.

3 years

FC1=CC=C(C=2C=3C(=NC(=CC3)C4=CC(OC)=CC(OC)=C4)NN2)C=C1

-20°C

12352200